Prime Therapeutics (Prime) will present the following managed care research posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2026 conference in San Diego from Oct. 26–29. 

These studies include:

• “Optimizing Secukinumab Dispensing for Cost Containment: Results From a Pharmacist-to-Prescriber Outreach Program”
  This research has earned a platinum award from AMCP.
• “Antiemetic Utilization Following Initiation of Glucagon-Like Peptide-1 Receptor Agonists to Treat Obesity Among Commercially Insured Members Without Diabetes: A 3-Year Real-World Assessment”
  This research has earned a gold award from AMCP.
• “Gastrointestinal Adverse Effects Following Initiation of Glucagon-Like Peptide-1 Receptor Agonists to Treat Obesity Among Commercially Insured Members Without Diabetes: A Three-Year Real-World Assessment”  
  This research has earned a gold award from AMCP.
• “Major Adverse Cardiovascular Events Following Initiation of Glucagon-Like Peptide-1 Receptor Agonists to Treat Obesity Among Commercially Insured Members Without Diabetes: A Three-Year Real-World Assessment” 
  This research has earned a silver award from AMCP.
• “Real-World Uptake and Characteristics of Commercially Insured Initiators of Oral Glucagon-Like Peptide-1 Receptor Agonists for Obesity Treatment”  
• “Glucagon-Like Peptide-1 Anti Obesity Medication Real World 1-Year Adherence Among a Commercially Insured Population in a Cardiometabolic Care Management Program”
• “Shifting Routes: Real-World Utilization, Costs and Site of Care of Intravenous and Subcutaneous Oncology Biologics”  

Prime subject matter experts will also present several education sessions during the conference. Explore the AMCP Nexus agenda for details.

And visit the Prime News & Insights page for more from AMCP Nexus 2026, or follow Prime on LinkedIn.